Compass Pathways PLC Stock News

COMPASS Pathways establishes Centre of Excellence with Sheppard Pratt to accelerate research and improve patient experience in mental health care

London, UK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,

Psilocybin Will Change Mental Health, Compass Pathways Could Be At The Forefront

These psychedelic stocks are worth accumulating on corrections. The companies are holding clinical trials for mental health drugs.

This small-cap biotech may very well revolutionize how we treat depression.

COMPASS Pathways is a biotech psychedelic medicine development and therapy company that has developed a synthetic formulation of psilocybin, COMP360, for combatting treatment-resistant depression. Rec

The company's fresh look at psychedelic drugs is attracting lots of attention.

The market is in its early stage, and the players in the space could have a lot of room to run.

Oregon just decriminalized the use of the psychedelic compound psilocybin. Could Compass Pathways, which is testing a synthetic form of the drug as a mental health therapy, be on the cusp of something

In this article we are going to list the 25 states that have the highest rates of depression in America. Click to skip ahead and jump to the 10 states that have the highest rates of depression in Amer

Oregon became the first state in the nation to legalize the therapeutic use of psychedelic mushrooms, raising awareness for this biotech's trailblazing treatment.

London, UK - 9 November 2020

London, UK, Nov. 05, 2020 (GLOBE NEWSWIRE) --   COMPASS Pathways plc to announce third quarter 2020 financial results on 12 November 2020

Voters in Oregon approved a ballot measure that legalizes a treatment this newly public company has in clinical trials.

London, UK, Nov. 04, 2020 (GLOBE NEWSWIRE) --   COMPASS Pathways plc to participate in Berenberg and Evercore investor conferences